Pneumococcal conjugate second or third-dose vaccines (PCVc) in Malta
Malta: Pneumococcal conjugate second or third-dose vaccines (PCVc) was 97.0% in 2025. ◆ Volatile
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Malta, 2008–2025
Source: World Health Organization, Global Health Observatory.
Analysis
The most recent figure for pneumococcal conjugate second or third-dose vaccines (pcvc) in Malta is 97.0%, measured in 2025. That is the highest value across all 18 years on record.
Over the whole period, pneumococcal conjugate second or third-dose vaccines (pcvc) in Malta peaked at 97.0% in 2024 and was at its lowest, 0.0%, in 2008.
Malta ranks 17th of 194 countries on this measure, in the top 10%.
The series is highly variable year to year, so single readings are best treated with caution.
Pneumococcal conjugate second or third-dose vaccines (PCVc) in Malta, year by year
| Year | Value | Change |
|---|---|---|
| 2008 | 0.0% | — |
| 2009 | 0.0% | — |
| 2010 | 0.0% | — |
| 2011 | 0.0% | — |
| 2012 | 0.0% | — |
| 2013 | 0.0% | — |
| 2014 | 0.0% | — |
| 2015 | 0.0% | — |
| 2016 | 0.0% | — |
| 2017 | 0.0% | — |
| 2018 | 0.0% | — |
| 2019 | 0.0% | — |
| 2020 | 0.0% | — |
| 2021 | 64.0% | — |
| 2022 | 45.0% | -29.7% |
| 2023 | 71.0% | +57.8% |
| 2024 | 97.0% | +36.6% |
| 2025 | 97.0% | +0.0% |
Malta compared with similar countries
- Malta's 97.0% is above the median for high income countries, which is 91.0%, 1.1× the median. (63 countries reporting)
- Malta's 97.0% is above the median for Middle East, North Africa, Afghanistan & Pakistan, which is 91.0%, 1.1× the median. (23 countries reporting)
Averages by decade
| Decade | Average | Lowest | Highest | Years |
|---|---|---|---|---|
| 2000s | 0.0% | 0.0% | 0.0% | 2 |
| 2010s | 0.0% | 0.0% | 0.0% | 10 |
| 2020s | 62.3% | 0.0% | 97.0% | 6 |
Countries ranked near Malta
More health data for Malta
- Un projection of annual infant deaths, annual growth rate 0 % change on previous year (2100)
- Heat deaths vs projected death rates, annual growth rate -1.1 % change on previous year (2090)
- Estimated changes in temperature-related death rates compared to projected death rates 1,737 deaths per 1,000 people (2090)
- Number of infants who die before age 1 4 deaths (2100)
- Neonatal tetanus - number of reported cases, gaps filled 0 (2025)
- Population ages 00-04, female, annual growth rate 0.1693 % change on previous year (2025)
- Population ages 00-04, female, per unit of GDP 0 units per US$ of GDP (2025)
- Population ages 00-04, female, per capita 0.0194 units per person (2025)
- Population ages 00-04, male, annual growth rate 0.1495 % change on previous year (2025)
- Population ages 00-04, male, per unit of GDP 0 units per US$ of GDP (2025)
Frequently asked questions
- What is pneumococcal conjugate second or third-dose vaccines (pcvc) in Malta?
- Pneumococcal conjugate second or third-dose vaccines (pcvc) in Malta was 97.0% in 2025, according to World Health Organization, Global Health Observatory.
- What is the highest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Malta?
- The highest recorded value was 97.0% in 2024.
- What is the lowest pneumococcal conjugate second or third-dose vaccines (pcvc) recorded in Malta?
- The lowest recorded value was 0.0% in 2008.
- How does Malta rank for pneumococcal conjugate second or third-dose vaccines (pcvc)?
- Malta ranks 17th out of 194 countries with data for 2025.
- Where does this Malta data come from?
- The figures come from World Health Organization, Global Health Observatory, published as part of Pneumococcal conjugate second or third-dose vaccines (PCVc) immunization coverage by the locally recommended age (%) (WUENIC). Statizoid updates them automatically from the source API.
Download this data
CSV · JSON — 18 observations, free to reuse under CC BY-NC-SA 3.0 IGO (WHO).